- Home
- VTVT vs LGVN Comparison
VTVT vs LGVN Comparison
Compare VTVT & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- LGVN
- Stock Information
- Founded
- VTVT 2015
- LGVN 2014
- Country
- VTVT United States
- LGVN United States
- Employees
- VTVT N/A
- LGVN N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- VTVT Health Care
- LGVN Health Care
- Exchange
- VTVT Nasdaq
- LGVN Nasdaq
- Market Cap
- VTVT 54.4M
- LGVN 17.6M
- IPO Year
- VTVT 2015
- LGVN 2021
- Fundamental
- Price
- VTVT $23.50
- LGVN $0.80
- Analyst Decision
- VTVT Strong Buy
- LGVN Strong Buy
- Analyst Count
- VTVT 2
- LGVN 2
- Target Price
- VTVT $35.50
- LGVN $6.50
- AVG Volume (30 Days)
- VTVT 4.8K
- LGVN 551.0K
- Earning Date
- VTVT 11-12-2025
- LGVN 11-04-2025
- Dividend Yield
- VTVT N/A
- LGVN N/A
- EPS Growth
- VTVT N/A
- LGVN N/A
- EPS
- VTVT N/A
- LGVN N/A
- Revenue
- VTVT $17,000.00
- LGVN $2,073,000.00
- Revenue This Year
- VTVT N/A
- LGVN N/A
- Revenue Next Year
- VTVT N/A
- LGVN N/A
- P/E Ratio
- VTVT N/A
- LGVN N/A
- Revenue Growth
- VTVT N/A
- LGVN 68.67
- 52 Week Low
- VTVT $12.62
- LGVN $0.63
- 52 Week High
- VTVT $26.99
- LGVN $2.31
- Technical
- Relative Strength Index (RSI)
- VTVT 64.63
- LGVN 43.76
- Support Level
- VTVT $19.80
- LGVN $0.81
- Resistance Level
- VTVT $25.30
- LGVN $0.85
- Average True Range (ATR)
- VTVT 1.20
- LGVN 0.05
- MACD
- VTVT 0.08
- LGVN -0.00
- Stochastic Oscillator
- VTVT 67.27
- LGVN 26.56
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.